Table 6 Costs of chemotherapy for advanced colorectal cancer in the world (USD, monthly)
Oxaliplatin-based regimens | Irinotecan-based regimens | Regimens including molecular targeted agents | |
|---|---|---|---|
Japan (Present study) | FOLFOX: 4,141 | IRIS: 2,217 | FOLFOX + Bev: 7,353 |
FOLFIRI (2nd line): 1,574 | FOLFIRI + Bev or Cet: 6,777 | ||
Japan (Miyazaki14) | FOLFOX: 4,151 | FOLFIRI: 2,398 | |
Japan (Shiroiwa15) | FOLFOX: 4,554 | FOLFIRI (2nd line): 2,376 | FOLFOX + Bev: 7,722 |
XELOX: 3,564 | IFL + Bev: 4,950 | ||
XELOX + Bev: 6,831 | |||
Japan (Ajima16) | FOLFOX: 5,352 | FOLFIRI: 3,743 | |
US (Mullins23) | FOLFOX: 60,179 (per patient) | FOLFIRI: 44,087 (per patient) | |
US (Tumeh24) | FOLFOX: 29,865 (per patient) | FOLFIRI: 24,551 (per patient) | |
US (Chu30) | FOLFOX: 14,300 | ||
XELOX: 11,473 | |||
UK (NICE:HTA200125) | FOLFOX: 5,718 | FOLFIRI: 5,975 | |
UK (NICE:HTA200826) | FOLFOX: 22,734 (per patient) | FOLFIRI: 23,017 (per patient) | |
UK (Tappenden27) | IFL: 40,998 (per patient) | IFL + Bev: 74,379 (per patient) | |
France (Perrocheau32) | FOLFOX: 23,597 (per patient) | ||
XELOX: 17,695 (per patient) | |||
Koria (Lee28) | FOLFIRI: 1,597 | Bev: 5,150 | |
UK (Ward31) | 5-FU/LV (Mayo): 2,065 | ||
Capecitabine: 1,225 | |||
UFT/LV: 1,944 | |||